These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 25473155)

  • 1. CYP2C19 polymorphism influences Helicobacter pylori eradication.
    Kuo CH; Lu CY; Shih HY; Liu CJ; Wu MC; Hu HM; Hsu WH; Yu FJ; Wu DC; Kuo FC
    World J Gastroenterol; 2014 Nov; 20(43):16029-36. PubMed ID: 25473155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.
    Saito Y; Serizawa H; Kato Y; Nakano M; Nakamura M; Saito H; Suzuki H; Kanai T
    World J Gastroenterol; 2015 Dec; 21(48):13548-54. PubMed ID: 26730167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
    Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
    Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
    Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
    Ormeci A; Emrence Z; Baran B; Gokturk S; Soyer OM; Evirgen S; Akyuz F; Karaca C; Besisik F; Kaymakoglu S; Ustek D; Demir K
    Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):879-85. PubMed ID: 27010145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.
    Oh JH; Dong MS; Choi MG; Yoo HW; Lee SB; Park YI; Chung IS
    J Gastroenterol Hepatol; 2009 Feb; 24(2):294-8. PubMed ID: 18823430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CYP2C19 Gene Polymorphisms on Proton Pump Inhibitor, Amoxicillin, and Levofloxacin Triple Therapy for Eradication of Helicobacter Pylori.
    Lin YA; Wang H; Gu ZJ; Wang WJ; Zeng XY; Du YL; Ying SS; Zhang BH
    Med Sci Monit; 2017 Jun; 23():2701-2707. PubMed ID: 28577017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics of proton pump inhibitors.
    Furuta T; Shirai N; Sugimoto M; Ohashi K; Ishizaki T
    Pharmacogenomics; 2004 Mar; 5(2):181-202. PubMed ID: 15016609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
    Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
    Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy.
    Ram M R; Teh X; Rajakumar T; Goh KL; Leow AHR; Poh BH; Mariappan V; Shankar EM; Loke MF; Vadivelu J
    J Antimicrob Chemother; 2019 Jan; 74(1):11-16. PubMed ID: 30403784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.
    Kang JM; Kim N; Lee DH; Park YS; Kim JS; Chang IJ; Song IS; Jung HC
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1287-91. PubMed ID: 18637061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy.
    Kuo CH; Wang SS; Hsu WH; Kuo FC; Weng BC; Li CJ; Hsu PI; Chen A; Hung WC; Yang YC; Wang WM; Wu DC
    Helicobacter; 2010 Aug; 15(4):265-72. PubMed ID: 20633187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication.
    Karaca RO; Kalkisim S; Altinbas A; Kilincalp S; Yuksel I; Goktas MT; Yasar U; Bozkurt A; Babaoglu MO
    Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):199-206. PubMed ID: 27611887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication.
    Ozdil B; Akkiz H; Bayram S; Bekar A; Akgöllü E; Sandikçi M
    Turk J Gastroenterol; 2010 Mar; 21(1):23-8. PubMed ID: 20533108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
    Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
    Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials.
    Tang HL; Li Y; Hu YF; Xie HG; Zhai SD
    PLoS One; 2013; 8(4):e62162. PubMed ID: 23646118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens.
    Shimoyama T; Chinda D; Sawada Y; Komai K; Chiba H; Saito Y; Sasaki Y; Matsuzaka M; Fukuda S
    Intern Med; 2017; 56(13):1621-1627. PubMed ID: 28674348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.
    Yang JC; Wang HL; Chern HD; Shun CT; Lin BR; Lin CJ; Wang TH
    Pharmacotherapy; 2011 Mar; 31(3):227-38. PubMed ID: 21361732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.